Key result
COVID-19 mRNA vaccination evaluation for acute myocarditis incidence reports no specific quantitative results.
Why the study?
Recent reports identified acute myocarditis following COVID-19 mRNA vaccine administration, prompting evaluation of its incidence and clinical outcomes in adults.
What is the incidence and clinical outcomes of acute myocarditis following COVID-19 mRNA vaccination in adults?
Observational
What is the incidence and clinical outcomes of acute myocarditis following COVID-19 mRNA vaccination in adults?
This study evaluates the incidence and clinical outcomes of acute myocarditis following COVID-19 mRNA vaccination in US adults.
May inform myocarditis risk counseling after mRNA vaccination; extends observational surveillance but leaves open causal confirmation.
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or OlderVaccination is an essential component of the public health strategy to end the COVID-19 pandemic.1-3 Recently, there have been reports of acute myocarditis following COVID-19 mRNA vaccine administration.4-6 We evaluated acute myocarditis incidence and clinical outcomes among adults following mRNA vaccination in an integrated health care system in the US.
No takes yet. Share an insight, caveat, or question.
Simone et al. (2021) conducted an observational in Acute myocarditis. COVID-19 mRNA vaccination was evaluated on Acute myocarditis incidence and clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: